zurück | Nieren - Karzinom: Prognose | ||
UICC-Stadium | |||
Stadium | 5a-Überleben | ||
I | 95% | ||
II | 89% | ||
III | 60% | ||
IV | 25% | ||
mRCC | metastasiertes Nierenzellkarzinom | ||
Motzer - Hudes - Kriterien | |||
|
max 1 Kriterium: Survival 2 Jahre - low risk > 2 Kriterien: Survival 4 - 8 Monate - high risk | ||
Quellen |
Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999):2530-2540 Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(2002):289-296 Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005):832-41. |
Impressum .....................................................................................Zuletzt geändert am 22.09.2012 15:31